OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Onco News

Search results for "Lynparza"

The PARP inhibitor, Olaparib ( Lynparza ) has shown clinical activity in subsets of recurrent ovarian cancer patients. Researchers have hypothesized increased DNA damage by Olaparib may complement a ...


Positive results from the phase 3 PAOLA-1 trial in women with advanced ovarian cancer. were announced. The trial, in the first-line maintenance setting, compared Olaparib ( Lynparza ) added to stand ...